Korean Journal of Acupuncture

Table. 3.

Table. 3.

Data of included studies

First author (year) Outcome measurement Treatment Main result (IG/CG)
1.Lin (2016)17) 1. TER IG CA+MR (+NKT) (CA=董氏奇穴) 1. 98% (49/50)/77.8% (35/45) (p<0.05)
CG WM
2.Deng (2016)18) 1. TER IG NKT+HM 1. 90% (27/30)/70% (21/30) (p<0.05)
CG CA
3.Hong (2017)19) 1. TER IG NKT+CA(CA=太极六合针) 1. 86.7% (26/30)/60% (18/30) (p<0.05)
CG CA
4.Yang (2017)20) 1. TER IG NKT 1. 89% (89/100)/77% (77/100) (p<0.05)
CG CA
5.Liang (2019)21) 1. TER
2. VAS
3. SAS
4. SDS		 IG NKT 1. 9,286.55% (28/29)/68.97% (20/29) (p<0.05)
2. 7.42±0.59→1.02±0.37/7.39±0.47→3.58±0.25 (p<0.05)
3. 72.63±4.52→10.15±0.29/71.94±5.26→21.45±0.38 (p<0.05)
4. 71.89±5.03→13.68±0.41/70.96±4.22→22.57±0.24 (p<0.05)
CG EA
6.Ma (2020)22) 1. TER IG NKT 1. 98% (39/40)/88% (35/40) (p<0.05)
CG EA
7.Fu (2021)23) 1. TER
2. VAS
3. HIT-6		 IG NKT 1. 83.3% (65/78)/57.7% (41/71) (p<0.05)
2. 7.95±1.66→3.52±1.68 (BT>AT: p<0.05)/7.15±1.34→5.16±1.61 (IG<CG: p<0.05)
3. 60.25±5.74→45.21±5.44 (BT>AT: p<0.01)/59.36±4.96→53.81±5.72 (IG<CG: p<0.05)
CG EA
8.Zhu (2021)24) 1. TER
2. VAS
3. SI		 IG NKT+HM 1. 96.67% (29/30)/73.33% (22/30) (p<0.05)
2. 8.08±0.81→3.13±1.58 (BT>AT: p<0.05)/8.17±0.86→4.48±1.67 (IG<CG: p<0.05) (deviation between AT and BT: 4.95±1.28/3.72±1.34 (p<0.05))
3. ① IL-6: 7.98±2.00→3.17±1.61 (BT>AT: p<0.05)/7.55±2.23→4.43±2.17 (IG<CG: p<0.05)
② hs-CRP: 5.55±2.08→1.65±1.10 (BT>AT: p<0.05)/5.45±2.12→2.98±1.69 (IG<CG: p<0.05)
CG WM
9.Wang (2022)25) 1. TER
2. VAS
3. TSS
4. SI		 IG NKT 1. 96.08% (49/51)/84.31% (43/51) (p<0.05)
2. 6.37±1.84 (BT)→3.51±1.06 (1 wk AT)→2.07±0.54 (2 wks AT)→0.89±0.07 (3 wks AT)/6.05±1.77 (BT)→4.52±1.23 (1 wk AT)→3.41±1.12 (2 wks AT)→1.95±0.85 (3 wks AT) (BT: p>0.05, AT: p<0.05)
3. ① Headache (头痛): 4.28±1.03→1.87±0.61/4.09±0.98→2.95±0.75
② Irritability (心烦易怒): 3.58±1.12→1.02±0.35/3.24±1.07→2.54±0.68
③ Red eyes (目赤): 4.15±1.21→1.23±0.25/3.96±1.13→1.97±0.53
④ Bitter mouth (口苦): 2.77±0.51→1.22±0.16/2.65±0.48→2.03±0.31 (BT: p>0.05, AT: p<0.05)
4. ① MMP-9: 118.29±10.53→80.54±8.22/117.94±10.27→89.71±9.03
② 5-HT: 72.35±10.51→97.66±15.46/71.79±10.42→91.34±14.57
③ NOS: 73.02±2.55→53.48±2.63/72.89±2.14→62.17±2.79 (BT: p>0.05, AT: p<0.05)
CG CA
10.Feng (2023)26) 1. TER
2. VAS
3. HSS
4. HIT-6		 IG NKT 1. ① 1 month AT: 93.94% (31/33)/87.10% (27/31)
② 3 months AT: 87.88% (29/33)/77.42% (24/31)
2. 7.00* (BT)→3.00* (1 month AT)→4.00* (3 months AT)/7.00* (BT)→4.00* (1 month AT)→5.00* (3 months AT)(BT>AT: p<0.05, IG<CG : p<0.05)
3. ① BT: no statistically significant difference in the each item of headache score and total scores between the two groups (p>0.05)
② 1 month, 3 months AT: each item of the headache score and the total score for both groups were significantly lower than BT (p<0.05)
③ The lower range: IG>CG (except for comorbidities and other symptoms) (p<0.05)
4. ① BT: no statistically significant difference in the each item of headache score and total scores between the two groups (p>0.05)
② 1 month, 3 months AT: each item of the headache score and the total score for both groups were significantly lower than BT (p<0.05)
③ The lower range: IG>CG (p<0.05)
CG WM

CA : common acupuncture (=毫鍼), MR : manipulative reduction, NKT : needle knife therapy (=acupotomy), WM : western medicine, HM : herbal medicine, EA : electro-acupuncture, TER : total efficacy rate, VAS : visual analogue scale, SAS : self-rating anxiety scale, SDS : self-rating depression scale, HIT-6 : headache impact test-6, BT : before treatment, AT : after treatment, SI : serological indicators, IL : interleukin, hs-CRP : high sensitivity-C reactive protein, TSS : traditional Chinese medicine symptom score, wk(s) : week(s), HSS : headache scale score, MP : metalloproteinases, HT : hydroxytryptamine, NOS : nitric oxide synthase, p : p-value. *Mean.
Korean J Acupunct 2023;40:62-78 https://doi.org/10.14406/acu.2023.011
© 2023 Korean J Acupunct